ArticleChinese medical journal2026
A cigarette compound-induced tumor microenvironment promotes sorafenib resistance in hepatocellular carcinoma via the 14-3-3η-modified tumor-associated proteome.
Article in Chinese medical journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Liver sinusoidal endothelial cells in liver diseases and hepatocellular carcinoma: molecular mechanisms, physiology, and therapies.Molecular biomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSorafenib resistance is the bottleneck in the clinical treatment of advanced hepatocellular carcinoma (HCC). Cigarette compounds accelerate HCC progression and chemotherapy resistance by forming a chemical microenvironment. Here, we aimed to further reveal the mechanisms by which the microenvironment formed by cigarette exposure contributes to sorafenib resistance.
methodsA cohort of 119 patients enrolled from the First Affiliated Hospital of Huzhou University (between Mar 2019 to Jan 2024) and the Second Affiliated Hospital of Nanjing Medical University (between Jan 2018 to Jan 2024) with advanced HCC who had recurrent disease and were receiving sorafenib treatment was analyzed. The public data of the expression of genes and survival of HCC patients were all obtained from The Cancer Genome Atlas (TCGA) database, and Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses were conducted by Database for Annotation, Visualization and Integrated Discovery (DAVID). The phospho/angiogenesis antibody arrays were used to identify the key phosphorylated proteins/cytokines that have been differentially modified. HCC cell lines and xenografted nude mice were used as experimental models. Quantitative real-time polymerase chain reaction (qPCR), Western blotting, immunofluorescence and immunohistochemistry (IHC) were used to elucidate the role of key factors in regulating sorafenib resistance. Flow cytometry, TdT-mediated dUTP nick end labeling, caspase activity, enzyme-linked immunosorbent assay, and capillary tube formation assay were employed to investigate related biological functions.
resultsChronic cigarette smoking exposure continuously activated 14-3-3η via an epigenetic accumulation of DNA demethylation. This "switch-like" factor, 14-3-3η, upregulated its key downstream pathway, B-Raf/extracellular regulated protein kinases (ERK). 14-3-3η and its regulated B-Raf/ERK protein jointly blocked the caspase cascade, enhancing the pro-survival ability of HCC cells. 14-3-3η/B-Raf/ERK activated nuclear factor kappa-B (NF-κB), which in turn transcriptionally upregulated multidrug resistance protein 1 (MDR1) and adenosine triphosphate (ATP) binding cassette transporter G2 (ABCG2), accelerating drug efflux. NF-κB also transcriptionally regulated vascular endothelial growth factor (VEGF) and granulocyte colony stimulating factor (G-CSF), inducing the neo-vascularization. These critical processes together resisted the HCC to sorafenib. Furthermore, these effects were blocked and sorafenib resistance was reversed when 14-3-3η was targeted with its novel chemical inhibitor, arsenic trioxide.
conclusionsA cigarette compound-formed tumor microenvironment conferred sorafenib resistance to HCC by locking the adaptor protein 14-3-3η in a constitutively active state. This outcome provided a mechanistic rationale and a translational strategy to re-sensitize HCC patients exposed to cigarette to targeted therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.